2022
Reemergence of Invasive Pneumococcal Disease in Germany During the Spring and Summer of 2021
Perniciaro S, van der Linden M, Weinberger DM. Reemergence of Invasive Pneumococcal Disease in Germany During the Spring and Summer of 2021. Clinical Infectious Diseases 2022, 75: 1149-1153. PMID: 35136983, PMCID: PMC9383454, DOI: 10.1093/cid/ciac100.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseIPD surveillance dataIPD casesIPD incidencePneumococcal diseaseNonpharmaceutical interventionsVaccine-serotype invasive pneumococcal diseaseSurveillance dataCoronavirus disease 2019 (COVID-19) pandemicSARS-CoV-2Disease 2019 pandemicVaccine serotypesChildren 0Baseline valuesAge groupsSerotype-specific variationPercentage changeOverall casesIncidenceNPI strategiesIPD levelAge distributionDiseaseBaselineSerotypes
2019
Limited indirect effects of an infant pneumococcal vaccination program in an aging population
van der Linden M, Imöhl M, Perniciaro S. Limited indirect effects of an infant pneumococcal vaccination program in an aging population. PLOS ONE 2019, 14: e0220453. PMID: 31369597, PMCID: PMC6675109, DOI: 10.1371/journal.pone.0220453.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseSerotype 3 invasive pneumococcal diseaseHerd protection effectsIPD casesAge groupsPCV13-type invasive pneumococcal diseaseAdult invasive pneumococcal diseaseAdult pneumococcal vaccinationPneumococcal vaccination programAdults 60 yearsVaccine serotypes 4Years of ageAdult age groupsIndirect protection effectPneumococcal vaccinationPneumococcal diseasePolysaccharide vaccineVaccine recommendationsChildhood vaccinationVaccination programVaccine formulationsAdult coverageAdults 60Protection effectSerotype 4
2016
Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany
van der Linden M, Falkenhorst G, Perniciaro S, Fitzner C, Imöhl M. Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany. PLOS ONE 2016, 11: e0161257. PMID: 27526117, PMCID: PMC4985133, DOI: 10.1371/journal.pone.0161257.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseasePneumococcal conjugate vaccineAdjusted vaccine effectivenessTimeliness of vaccinationVaccine effectivenessPost boosterConjugate vaccinePneumococcal diseaseVaccine-type invasive pneumococcal diseaseType invasive pneumococcal diseaseIndirect cohort methodOverall vaccine effectivenessPneumococcal conjugate vaccinationSpecific vaccine effectivenessNumber of dosesYears of ageResidual casesTime of infectionConjugate vaccinationPCV13 serotypesPCV7 serotypesFirst doseIPD casesUnvaccinated childrenVaccination status
2015
Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany
van der Linden M, Falkenhorst G, Perniciaro S, Imöhl M. Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany. PLOS ONE 2015, 10: e0131494. PMID: 26132078, PMCID: PMC4488910, DOI: 10.1371/journal.pone.0131494.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overChildChild, PreschoolFemaleGenes, BacterialGermanyHeptavalent Pneumococcal Conjugate VaccineHumansImmunization ProgramsImmunologic SurveillanceInfantInfant, NewbornMaleMiddle AgedPneumococcal InfectionsPneumococcal VaccinesRNA, Ribosomal, 16SSerogroupSerotypingStreptococcus pneumoniaeVaccinationConceptsEarly vaccination periodPneumococcal conjugate vaccinationInvasive pneumococcal diseaseVaccination periodConjugate vaccinationPCV7 serotypesIPD casesPneumococcal diseaseQuellung methodSerotype distributionChildhood pneumococcal conjugate vaccinationNon-vaccinated age groupsAge groupsGerman National Reference CenterPre-vaccination periodSerotype 1Streptococcus pneumoniae isolatesNational Reference CenterMicrobiological diagnostic laboratorySerotype 10AInfant vaccinationVaccine serotypesSerotype 19ASeparate age groupsPneumoniae isolates